Gold’s record-breaking run comes as stocks hit fresh highs. Is it too late for investors?

Date:

Share post:




Gold is on a tear, rising repeatedly to never-before-seen price levels this year — and its rally shows few signs of a slowdown anytime soon thanks to demand from central banks and falling real interest rates. That has left investors to seek out the best way to gain exposure to the precious metal.



Source link

Alexandra Williams
Alexandra Williams
Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

Recent posts

Related articles

Stock market ‘finally paying more attention to tariffs’ as a potential headwind

Tariffs have taken the spotlight as a policy issue as S&P 500 companies have discussed earnings with...

Investors are bracing for higher-for-even-longer interest rates

Friday’s stronger-than-expected economic data, combined with fresh remarks from Federal Reserve Chairman Jerome Powell on Thursday, were...

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs...

Manufacturing activity surges in New York region to highest level in nearly three years

The New York Federal Reserve’s Empire State business conditions index, a gauge of manufacturing activity in the...

RFK Jr. would rattle health markets as head of HHS, but his confirmation is far from certain, analyst says

Robert F. Kennedy Jr. would create “significantly more volatility” in health markets if he is confirmed as...

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine...

Powell says Fed doesn’t need to hurry to cut interest rates

Federal Reserve Chair Jerome Powell said Thursday that the economy is in a good place, with inflation...

Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease...